Cornelia Then1,2, Holger Then3, Christa Meisinger4,5, Margit Heier6, Annette Peters6,7, Wolfgang Koenig8,9,10, Wolfgang Rathmann11, Jürgen Scherberich12, Jochen Seissler1,2. 1. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Germany. 2. Clinical Cooperation Group Diabetes, Ludwig-Maximilians-Universität München and Helmholtz Zentrum München, Munich, Germany. 3. Freie Waldorfschule Augsburg, Germany. 4. Independent Research Group Clinical Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, Germany. 5. Chair of Epidemiology at UNIKAT Augsburg, Ludwig-Maximilians-Universität München, Munich, Germany. 6. Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, Germany. 7. Research Unit of Molecular Epidemiology, German Research Center for Environmental Health, Neuherberg, Germany. 8. Institute of Epidemiology and Biostatistics, University of Ulm, Ulm, Germany. 9. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. 10. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. 11. German Diabetes Center, Leibniz Institute at Heinrich Heine University Düsseldorf, Institute of Biometrics and Epidemiology, Düsseldorf, Germany. 12. Klinikum München-Harlaching, Teaching Hospital of the Ludwig-Maximilians-Universität, Munich, Germany.
Abstract
AIMS: Serum uromodulin has recently emerged as promising biomarker for kidney function and was suggested to be associated with type 2 diabetes (T2D) in coronary patients. Here, we analyzed the association of serum uromodulin with T2D in the population-based KORA F4/FF4 study. METHODS: In 1119 participants of the KORA F4 study aged 62 - 81 years, serum uromodulin was measured and the association of serum uromodulin with T2D was assessed using logistic and linear regression models stratified for sex. After a mean follow-up time of 6.5 years, 635 participants where reevaluated. Glucose tolerance status was determined by oral glucose tolerance test at baseline and at the follow-up examination except in cases of known T2D. RESULTS: Serum uromodulin was inversely associated with T2D in the crude analysis and after adjustment for age and BMI in men (p < 0.001) and in women (p < 0.05). After further adjustment for estimated glomerular filtration rate, serum uromodulin was significantly inversely associated with T2D in men (p < 0.001), but not in women. Serum uromodulin was not associated with prediabetes after multivariate adjustment and did not predict T2D in men or in women after the follow-up time of 6.5 ± 0.3 years. CONCLUSIONS: In participants of the KORA F4 study, serum uromodulin is independently associated with T2D in men, but is no predictor of future development of T2D.
AIMS: Serum uromodulin has recently emerged as promising biomarker for kidney function and was suggested to be associated with type 2 diabetes (T2D) in coronary patients. Here, we analyzed the association of serum uromodulin with T2D in the population-based KORA F4/FF4 study. METHODS: In 1119 participants of the KORA F4 study aged 62 - 81 years, serum uromodulin was measured and the association of serum uromodulin with T2D was assessed using logistic and linear regression models stratified for sex. After a mean follow-up time of 6.5 years, 635 participants where reevaluated. Glucose tolerance status was determined by oral glucose tolerance test at baseline and at the follow-up examination except in cases of known T2D. RESULTS: Serum uromodulin was inversely associated with T2D in the crude analysis and after adjustment for age and BMI in men (p < 0.001) and in women (p < 0.05). After further adjustment for estimated glomerular filtration rate, serum uromodulin was significantly inversely associated with T2D in men (p < 0.001), but not in women. Serum uromodulin was not associated with prediabetes after multivariate adjustment and did not predict T2D in men or in women after the follow-up time of 6.5 ± 0.3 years. CONCLUSIONS: In participants of the KORA F4 study, serum uromodulin is independently associated with T2D in men, but is no predictor of future development of T2D.
Authors: Cornelia Then; Holger L Then; Andreas Lechner; Barbara Thorand; Christa Meisinger; Margit Heier; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Jürgen Scherberich; Jochen Seissler Journal: Clin Kidney J Date: 2020-05-01
Authors: Yong Li; Yurong Cheng; Francesco Consolato; Guglielmo Schiano; Michael R Chong; Maik Pietzner; Ngoc Quynh H Nguyen; Nora Scherer; Mary L Biggs; Marcus E Kleber; Stefan Haug; Burulça Göçmen; Marie Pigeyre; Peggy Sekula; Inga Steinbrenner; Pascal Schlosser; Christina B Joseph; Jennifer A Brody; Morgan E Grams; Caroline Hayward; Ulla T Schultheiss; Bernhard K Krämer; Florian Kronenberg; Annette Peters; Jochen Seissler; Dominik Steubl; Cornelia Then; Matthias Wuttke; Winfried März; Kai-Uwe Eckardt; Christian Gieger; Eric Boerwinkle; Bruce M Psaty; Josef Coresh; Peter J Oefner; Guillaume Pare; Claudia Langenberg; Jürgen E Scherberich; Bing Yu; Shreeram Akilesh; Olivier Devuyst; Luca Rampoldi; Anna Köttgen Journal: JCI Insight Date: 2022-05-23
Authors: Cornelia Then; Holger Then; Andreas Lechner; Cornelia Huth; Christa Meisinger; Margit Heier; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Christian Herder; Michael Roden; Jürgen Scherberich; Jochen Seissler Journal: Endocr Connect Date: 2019-10 Impact factor: 3.335
Authors: Cornelia Then; Christian Herder; Holger Then; Barbara Thorand; Cornelia Huth; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Michael Stumvoll; Haifa Maalmi; Thomas Meitinger; Andreas Lechner; Jürgen Scherberich; Jochen Seissler Journal: Clin Kidney J Date: 2020-09-06